secwatch.observer — SEC 8-K summary
======================================

Issuer:     UTAH MEDICAL PRODUCTS INC (UTMD)
CIK:        0000706698
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001096906-24-000127
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01, 99.1
LLM model:  deepseek-v4-flash:cloud@v2

UTMD FY2023 EPS up 1% on interest income; revenue down 4%, litigation costs rise
--------------------------------------------------------------------------------

- Full year revenue $50.2M (-4% YoY); EPS $4.574 (+1.2%) as lower operating income offset by higher interest income.
- Q4 revenue $12.3M (-9%); net income $4.3M (-6%); gross margin fell to 57.6% from 61.3%.
- Operating income down 15% due to $2.9M biopharma OEM decline and $1.66M litigation costs vs $0.67M in 2022.
- Cash & investments rose to $92.9M; quarterly dividend increased to $0.30/share starting Jan 2024.
- Management expects further GP margin dilution in 2024 as biopharma sales projected to decline significantly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/706698/000109690624000127/0001096906-24-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/706698/000109690624000127/utmd-20240130.htm
  HTML page:      https://secwatch.observer/filing/0001096906-24-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer